N-[(3aS,4R,6S,6aR)-Tetrahydro-6-(2-hydroxyethoxy)-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]carbamic acid phenylmethyl ester

Product Details

CAS No:274693-54-8

MF:C18H25NO6

Appearance:colorless or light-yellow transparent liquid

Specification:98.5%

UN number:-

Package:1/5/10/25kgs/drum

Supply Capacity:MT

Synonyms:CarbaMic acid, [(3aS,4R,6S,6aR)-tetrahydro-6-(2-hydroxyethoxy)-2,2-diMethyl-4H-cyclopenta-1,3-dioxol-4-yl]-, phenylMethyl ester;Ticagrelor Related Compound II;N-[(3aS,4R,6S,6aR)-Tetrahydro-6-(2-hydroxyethoxy)-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]carbamic acid phenylmethyl ester;benzyl 6-(2-hydroxyethoxy)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ylcarbamate;Carbamic acid, N-[(3aS,4R,6S,6aR)-tetrahydro-6-(2-hydroxyethoxy)-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]-, phenylmethyl ester;N-[(3aS,4R,6S,6aR)-Tetrahydro-6-(2-hydroxyethoxy)-2,2-dimeth...;Ticagrelor Impurity (intermediate) TGK-10;Ticagrelor Related Compound 110; 274693-54-8; DTXSID701106755; Phenylmethyl N-[(3aS,4R,6S,6aR)-tetrahydro-6-(2-hydroxyethoxy)-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]carbamate; Phenylmethyl N-((3aS,4R,6S,6aR)-tetrahydro-6-(2-hydroxyethoxy)-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl)carbamate; RefChem:1095055; DTXCID901538413; Benzyl ((3aS,4R,6S,6aR)-6-(2-hydroxyethoxy)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)carbamate; MFCD22419928; Ticagrelor Impurity 18; CID 9924588; benzyl N-[(3aR,4S,6R,6aS)-4-(2-hydroxyethoxy)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-6-yl]carbamate; N-[(3aS,4R,6S,6aR)-Tetrahydro-6-(2-hydroxyethoxy)-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]carbamic acid phenylmethyl ester; 1423768-24-4; BENZYL ((3AS,4R,6S,6AR)-6-(2-HYDROXYETHOXY)-2,2-DIMETHYLTETRAHYDRO-4H-CYCLOPENTA[D][1,3]DIOXOL-4-YL)CARBAMATE; n-((3as,4r,6s,6ar)-tetrahydro-6-(2-hydroxyethoxy)-2,2-dimethyl-4h-cyclopenta-1,3-dioxol-4-yl)carbamic acid phenylmethyl ester; Ticagrelor Impurity 336; SCHEMBL10249654; CS-M2434; AKOS030632713; DS-19240; SY317706; F516543; 2-[[(3aR,4S,6R,6aS)-6-(Cbz-amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy]ethanol; rel-Benzyl ((3aS,4R,6S,6aR)-6-(2-hydroxyethoxy)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)carbamate

Product application:N-[(3aS,4R,6S,6aR)-Tetrahydro-6-(2-hydroxyethoxy)-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]carbamic acid phenylmethyl ester,274693-54-8,Ticagrelor intermediate,Ticagrelor cyclopentane intermediate,Ticagrelor Cbz derivative,Benzyl ((3aS,4R,6S,6aR)-6-(2-hydroxyethoxy)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)carbamate,P2Y12 receptor antagonist precursor,Antiplatelet API intermediate,Antithrombotic drug intermediate,Chiral cyclopentane building block,Pharmaceutical grade Ticagrelor intermediate,Cardiovascular drug intermediate,Enantiopure API synthon,Fine organic chemical intermediate,High purity Ticagrelor intermediate 99%,CAS 274693-54-8 manufacturer China,274693-54-8 supplier,Suzhou Health Chemicals chiral building blocks,Ticagrelor intermediate wholesale bulk export

 

N-[(3aS,4R,6S,6aR)-Tetrahydro-6-(2-hydroxyethoxy)-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]carbamic acid phenylmethyl ester serves as an indispensable, ultra-pure enantiopure cyclopentane building block, premier active pharmaceutical ingredient (API) intermediate, and versatile chiral synthon extensively utilized across cardiovascular medicinal chemistry, commercial antithrombotic manufacturing, and advanced asymmetric pharmaceutical synthesis sectors. In active pharmaceutical ingredient (API) manufacturing and clinical drug discovery, universally recognized as the flagship chiral intermediate for the blockbuster antiplatelet and antithrombotic therapy Ticagrelor, its molecular architecture incorporates four contiguous, exquisitely defined stereocenters (3aS, 4R, 6S, 6aR) arranged on a rigid cyclopentane ring, flanked by an acetonide-protected cis-diol, an extended hydroxyethoxy ether handle, and a Cbz-protected chiral amine group; through selective, high-yielding catalytic hydrogenolysis to cleave the benzyl carbamate protective group, it liberates an optically pure primary amine that undergoes regioselective nucleophilic substitution with functionalized triazolopyrimidine or pyrimidine core intermediates, followed by mild acidic deprotection of the acetonide unit to deliver the complete, biologically active Ticagrelor molecular scaffold without stereochemical erosion; this commercial synthesis supports global supply chains for critical clinical therapies prescribed to manage acute coronary syndromes, reduce stent thrombosis following percutaneous coronary intervention (PCI), and prevent secondary myocardial infarction and ischemic stroke events. In receptor pharmacology and chemical biology, this advanced building block is deployed to synthesize next-generation reversible P2Y12 purinergic receptor antagonists, allosteric platelet modulators, and fluorescent molecular binding probes. In biomedical materials and functional polymers, its chiral derivatives serve as functional monomers for engineering biocompatible hydrogels and targeted drug-eluting matrices. Furthermore, in specialized chiral stationary phases, liquid crystalline alignment layers, and asymmetric coordination ligands for fine chemical synthesis, chemical architectures derived from this compound deliver extraordinary stereochemical integrity, synthetic reliability, and broad multi-industry performance.